The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Learn more about whether Roivant Sciences Ltd. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the ...

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGSNet product sales of FILSPARI ...

Nephrolithiasis is an increasingly prevalent disorder in the elderly that is associated with multiple comorbid conditions such as hypertension, coronary artery disease, diabetes and CKD. Care of ...

Travere Therapeutics (TVTX) reported $74.79 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 66%. EPS of -$0.73 for the same period compares to -$1 ...

Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net product sales totaled $74 million in 4Q 2024; $227 million for full year 2024 SAN DIEGO, Feb. 20 ...